| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 01/16/2002 | EP1171155A2 Therapeutic compositions and methods for enhancing angiogenesis |
| 01/16/2002 | EP1171154A2 Uses of mammalian ox2 protein and related reagents |
| 01/16/2002 | EP1171149A1 Inhibition of proteasome function induces programmed cell death in endothelial cells |
| 01/16/2002 | EP1171143A1 Peptide extract of lupine and pharmaceutical or cosmetic or nutritional composition comprising same |
| 01/16/2002 | EP1171142A1 Inflammatory mediation obtained from atractylodes lancea |
| 01/16/2002 | EP1171136A2 Immunomodulating composition for use especially in the treatment of inflammations, infections and surgical adhesions |
| 01/16/2002 | EP1171130A1 Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same |
| 01/16/2002 | EP1171115A1 Methods of delivery of cetyl myristoleate |
| 01/16/2002 | EP1171113A1 Compounds useful as phosphotyrosine mimics |
| 01/16/2002 | EP1171100A1 Solubilized pharmaceutical composition for parenteral administration |
| 01/16/2002 | EP1171097A1 A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate |
| 01/16/2002 | CN1331701A Modified peptides as therapeutic agents |
| 01/16/2002 | CN1331689A 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles |
| 01/16/2002 | CN1331688A Aminopyrazole derivatives |
| 01/16/2002 | CN1331679A 3-azabicyclo [3.1.0] hexane derivatives as opiate receptors ligands |
| 01/16/2002 | CN1331674A Sulfonamide hydroxamates |
| 01/16/2002 | CN1331598A Medicinal compsns. for treating osseous lesion in multiple myeloma |
| 01/16/2002 | CN1331593A Pharmaceutical compsns. contg. tetrahydroisoquinoline compounds |
| 01/16/2002 | CN1331592A Liposomic niflumic acid-new transdermal anti-inflammatory medicine |
| 01/16/2002 | CN1077885C Biphenylsulfonamide matrix metalloproteinase inhibitors |
| 01/16/2002 | CN1077792C Pyridylbisphosphonates for use as therapeutical agent |
| 01/15/2002 | US6339160 For therapy of tumoral growth and metastatization, aterosclerosis, multiple sclerosis, alzheimer's disease, osteoporosis, hypertension, rheumatoid arthritis and other inflammatory diseases |
| 01/15/2002 | US6339094 2-acylaminopropanamines as tachykinin receptor antagonists |
| 01/15/2002 | US6339092 Metalloprotease inhibitors |
| 01/15/2002 | US6339083 Multiheterocyclic pharmAceuticals |
| 01/15/2002 | US6339082 Tricyclic compounds, preparation method and said method intermediates, application as medicines and pharmaceutical compositions containing same |
| 01/10/2002 | WO2002002797A2 Regulation of human 11 beta-hydroxysteroid dehydrogenase 1-like enzyme |
| 01/10/2002 | WO2002002771A2 Human sparc-homologous (hsparc-h1) gene and methods and uses thereof |
| 01/10/2002 | WO2002002755A2 Regulation of human thimet oligopeptidase-like enzyme |
| 01/10/2002 | WO2002002744A2 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof |
| 01/10/2002 | WO2002002640A2 Antibodies to human mcp-1 |
| 01/10/2002 | WO2002002638A2 Methods for treating rheumatic diseases using a soluble ctla4 molecule |
| 01/10/2002 | WO2002002634A2 Human extracellular matrix and cell adhesion polypeptides |
| 01/10/2002 | WO2002002633A2 Transporters and ion channels |
| 01/10/2002 | WO2002002629A2 Grf2-binding proteins and applications thereof |
| 01/10/2002 | WO2002002625A2 Novel fibroblast growth factors and nucleic acids encoding same |
| 01/10/2002 | WO2002002603A2 Protein modification and maintenance molecules |
| 01/10/2002 | WO2002002587A1 B7-like polynucleotides, polypeptides, and antibodies |
| 01/10/2002 | WO2002002566A1 Therapeutic compounds and methods |
| 01/10/2002 | WO2002002556A2 AZA-BRIDGED-BICYCLIC AMINO ACID DERIVATIVES AS α4 INTEGRIN ANTAGONISTS |
| 01/10/2002 | WO2002002554A1 Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders |
| 01/10/2002 | WO2002002551A1 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
| 01/10/2002 | WO2002002541A2 Inhibitors of copper-containing amine oxidases |
| 01/10/2002 | WO2002002511A1 Substituted benzamides for immune enhancement and for the treatment of cancer, infection and manic-depressive illness |
| 01/10/2002 | WO2002002136A1 Medicinal components comprising human parathyroid hormone and medicinal compositions for nasal administration containing the components |
| 01/10/2002 | WO2002002111A1 Dermal therapeutic system containing non-steroidal antiphlogistics with selective cox-2 inhibition |
| 01/10/2002 | WO2002002095A2 Compositions for treating bacterial infections containing oxazolidinone compound, sulbactam and an ampicillin |
| 01/10/2002 | WO2002002090A2 Inhibitors of copper-containing amine oxidases |
| 01/10/2002 | WO2002002051A2 Use of a polysaccharide excreted by the vibrio diabolicus species in bone repair |
| 01/10/2002 | WO2002001969A1 Vitamin k and essential fatty acids |
| 01/10/2002 | WO2001059071A3 Methods of preparing and using a viral vector library |
| 01/10/2002 | WO2001056993A3 Pyrazole compositions useful as inhibitors of erk |
| 01/10/2002 | WO2001044455A3 Antisense oligonucleotides for the inhibition of expression of type i procollagen |
| 01/10/2002 | WO2001043691A3 Fragments and antagonists of heat shock protein 60 |
| 01/10/2002 | WO2001042192A3 Vla-4 integrin antagonists |
| 01/10/2002 | WO2001036425A3 Imidazole compounds used as phosphodiesterase vii inhibitors |
| 01/10/2002 | WO2000055332A3 Human regulators of intracellular phosphorylation |
| 01/10/2002 | US20020004520 Crystalline(-)-3r,4r-trans-7methoxy-2,2-dimethyl-3-phenyl-4-{4-[2- (pyrrolidin-1-yl)ethoxy]pheny 1}chromane, hydrogen malete |
| 01/10/2002 | US20020004497 Combination injection preparation |
| 01/10/2002 | US20020004496 Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators |
| 01/10/2002 | US20020004489 Retinoid receptor interacting polynucleotides, polypeptides, and antibodies |
| 01/10/2002 | US20020004218 Bone disorders therapy |
| 01/10/2002 | CA2630062A1 Methods for treating graft versus host disease and immune disorders associated with rejection using a soluble ctla4 molecule |
| 01/10/2002 | CA2415123A1 Novel fibroblast growth factors and nucleic acids encoding same |
| 01/10/2002 | CA2415088A1 Aza-bridged-bicyclic amino acid derivatives as .alpha.4 integrin antagonists |
| 01/10/2002 | CA2414966A1 A pharmaceutical component based on human parathyroid hormone and a pharmaceutical composition for intranasal administration containing the component |
| 01/10/2002 | CA2414807A1 Inhibitors of copper-containing amine oxidases |
| 01/10/2002 | CA2414799A1 Inhibitors of copper-containing amine oxidases |
| 01/10/2002 | CA2414468A1 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
| 01/10/2002 | CA2413715A1 Grf2-binding proteins and applications thereof |
| 01/10/2002 | CA2413243A1 Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders |
| 01/10/2002 | CA2413186A1 Extracellular matrix and cell adhesion molecules |
| 01/10/2002 | CA2413128A1 Transporters and ion channels |
| 01/10/2002 | CA2412872A1 Protein modification and maintenance molecules |
| 01/10/2002 | CA2412775A1 Antibodies to human mcp-1 |
| 01/10/2002 | CA2412620A1 Vitamin k and essential fatty acids |
| 01/10/2002 | CA2406649A1 B7-like polynucleotides, polypeptides, and antibodies |
| 01/09/2002 | EP1170594A2 Methods for the identification of compounds useful for the treatment of disease states mediated by Prostaglandin D2 |
| 01/09/2002 | EP1169448A1 Tumor necrosis factor homologs and nucleic acids encoding the same |
| 01/09/2002 | EP1169445A2 Human proteins and polynucleotides encoding them |
| 01/09/2002 | EP1169442A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 01/09/2002 | EP1169440A1 48 human secreted proteins |
| 01/09/2002 | EP1169348A1 Purposeful movement of human migratory cells away from an agent source |
| 01/09/2002 | EP1169344A1 47 human secreted proteins |
| 01/09/2002 | EP1169338A2 Low-molecular inhibitors of complement proteases |
| 01/09/2002 | EP1169337A2 Steroid nitrates for the treatment of oxidative injury and endothelial dysfunction |
| 01/09/2002 | EP1169336A1 Ent-steroids as selectively active estrogens |
| 01/09/2002 | EP1169333A1 49 human secreted proteins |
| 01/09/2002 | EP1169326A1 Process for preparing alendronic acid |
| 01/09/2002 | EP1169317A1 Triarylimidazoles |
| 01/09/2002 | EP1169306A1 Dibenzoazulene derivatives for treating thrombosis, osteoporosis, arteriosclerosis |
| 01/09/2002 | EP1169302A1 N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists |
| 01/09/2002 | EP1169298A2 Pharmaceutical compounds |
| 01/09/2002 | EP1169058A1 Insulin-like growth factor binding protein-4 protease |
| 01/09/2002 | EP1169056A1 Caspase inhibitors for inhibiting blood cell proliferation and for treating autoimmune diseases |
| 01/09/2002 | EP1169049A2 Treatment of myeloma bone disease with proteasomal and nf-kappa-b activity inhibitors |
| 01/09/2002 | EP1169042A1 Dibenzo-azepine derivatives as alpha v integrin receptor antagonists |
| 01/09/2002 | EP1169038A1 Cyclic protein tyrosine kinase inhibitors |
| 01/09/2002 | EP1169027A1 Treatment of osteoarthritis |
| 01/09/2002 | EP1169005A2 Association of no-synthase inhibitor(s) and metabolic antioxidant(s) |